Oxazaphosphorines: new therapeutic strategies for an old class of drugs

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Expert Opinion on Drug Metabolism & Toxicology

• Publication date

  2010-07-19

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1517/17425255.2010.487861PMID 20446865
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targets of chloroacetaldehyde-induced nephrotoxicity.

  2010cited by this paper
• Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.

  2010cited by this paper
• Ten‐year follow‐up of a phase 2 study of dose‐intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor‐prognosis, advanced‐stage epithelial ovarian cancer

  2010cited by this paper
• A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia.

  2010cited by this paper
• Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients

  2009cited by this paper
• Influence of Glomerular Filtration Rate on the Pharmacokinetics of Cyclophosphamide Enantiomers in Patients With Lupus Nephritis

  2009cited by this paper
• New Ifosfamide Analogs Designed for Lower Associated Neurotoxicity and Nephrotoxicity with Modified Alkylating Kinetics Leading to Enhanced in Vitro Anticancer Activity

  2009cited by this paper
• Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients

  2009cited by this paper
• Children's toxicology from bench to bed--Drug-induced renal injury (3): Drug transporters and toxic nephropathy in childhood.

  2009cited by this paper
• D-19575—a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport

  2009cited by this paper
• Long-term evaluation of Ifosfamide-related nephrotoxicity in children.

  2009cited by this paper
• Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.

  2008cited by this paper
• Predictive Physiologically Based Pharmacokinetic Model for Antibody-Directed Enzyme Prodrug Therapy

  2008cited by this paper
• Neurotoxicity during ifosfamide treatment in children.

  2008cited by this paper
• Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients.

  2008cited by this paper
• In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro

  2008cited by this paper
• N‐Acetylcysteine prevents ifosfamide‐induced nephrotoxicity in rats

  2008cited by this paper
• Ifosfamide toxicity in cultured proximal renal tubule cells

  2007cited by this paper
• Ifosfamide‐induced nephrotoxicity in 593 sarcoma patients: A report from the Late Effects Surveillance System

  2007cited by this paper
• Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis.

  2007cited by this paper
• Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation

  2007cited by this paper
• Design of new oxazaphosphorine anticancer drugs.

  2007cited by this paper
• Encéphalopathie induite par l'ifosfamide : 15 observations

  2006cited by this paper
• Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.

  2006cited by this paper
• Role of thiamine in managing ifosfamide-induced encephalopathy

  2006influential reference
• Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy.

  2006cited by this paper
• Clinical Pharmacology of Cyclophosphamide and Ifosfamide

  2006cited by this paper
• Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis

  2006cited by this paper
• Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite

  2006cited by this paper
• Ifosfamide neurotoxicity: An atypical presentation with psychiatric manifestations

  2006cited by this paper
• [Ifosfamide induced encephalopathy: 15 observations].

  2006cited by this paper
• Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide

  2006cited by this paper
• Methylene Blue for Management of Ifosfamide-Induced Encephalopathy

  2006cited by this paper
• Pharmacokinetics of N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in the rat

  2006cited by this paper
• Metabolism and pharmacokinetics of oral and intravenous ifosfamide

  2005cited by this paper
• ENANTIOSELECTIVE METABOLISM AND CYTOTOXICITY OF R-IFOSFAMIDE AND S-IFOSFAMIDE BY TUMOR CELL-EXPRESSED CYTOCHROMES P450

  2005cited by this paper
• Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma

  2005cited by this paper
• A tubule cell model for ifosfamide nephrotoxicity.

  2005influential reference
• CONTRIBUTION OF CYP3A5 TO HEPATIC AND RENAL IFOSFAMIDE N-DECHLOROETHYLATION

  2005cited by this paper
• Chloroacetaldehyde- and acrolein-induced death of human proximal tubule cells

  2005cited by this paper
• High‐dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity

  2005cited by this paper
• Anti‐CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis

  2005cited by this paper
• Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy

  2004cited by this paper
• Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?

  2004influential reference
• Experimental toxicology of ASTA Z 7557 (INN mafosfamide)

  2004cited by this paper
• Enzyme-Catalyzed Activation of Anticancer Prodrugs

  2004cited by this paper
• Trofosfamide metabolism in different species-ifosfamide is the predominant metabolite

  2004cited by this paper
• Investigations on the pharmacokinetics of trofosfamide and its metabolites—first report of 4-hydroxy-trofosfamide kinetics in humans

  2004cited by this paper
• Trofosfamide in the Palliative Treatment of Cancer: A Review of the Literature

  2004cited by this paper
• Human aldehyde dehydrogenases: Potential pathological, pharmacological, and toxicological impact

  2003cited by this paper
• Clinical and cellular pharmacology in relation to solid tumours of childhood.

  2003cited by this paper
• Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells.

  2003cited by this paper
• Treatment of ifosfamide encephalopathy with intravenous thiamin.

  2003cited by this paper
• Chronic ifosfamide nephrotoxicity in children.

  2003cited by this paper
• Toxicity of chloroacetaldehyde is similar in adult and pediatric kidney tubules

  2002cited by this paper
• Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man

  2002cited by this paper
• Ifosfamide-induced encephalopathy.

  2002cited by this paper
• Cytochrome P450-based cancer gene therapy: current status

  2002cited by this paper
• Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells.

  2001cited by this paper
• Selective protection by stably transfected human ALDH3A1 (but not human ALDH1A1) against toxicity of aliphatic aldehydes in V79 cells.

  2001cited by this paper
• Synthesis of side‐chain‐substituted ifosfamide analogs

  2001cited by this paper
• Anodic oxidation of ifosfamide and cyclophosphamide: a biomimetic metabolism model of the oxazaphosphorinane anticancer drugs.

  2001cited by this paper
• Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide.

  2001cited by this paper
• Insights into the mechanisms of ifosfamide encephalopathy: drug metabolites have agonistic effects on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors and induce cellular acidification in mouse cortical neurons.

  2001influential reference
• Young age and the risk for ifosfamide-induced nephrotoxicity: a critical review of two opposing studies

  2001cited by this paper
• Necrotic, rather than apoptotic, cell death caused by cytochrome P450–activated ifosfamide

  2001cited by this paper
• Painful peripheral neuropathy after treatment with high-dose ifosfamide.

  2001cited by this paper
• Apoptosis and cancer chemotherapy.

  2001cited by this paper
• Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer

  2001cited by this paper
• Subacute Central Nervous System Degeneration in a Child: An Unusual Manifestation of Ifosfamide Intoxication

  2000cited by this paper
• Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide

  2000cited by this paper
• Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study

  2000cited by this paper
• Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide.

  2000cited by this paper
• Metabolism and Pharmacokinetics of Oxazaphosphorines

  2000cited by this paper
• Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature

  2000cited by this paper
• Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.

  1999cited by this paper
• Mechanisms of resistance to the toxicity of cyclophosphamide.

  1999cited by this paper
• Cyclophosphamide versus ifosfamide: to use ifosfamide or not to use, that is the three-dimensional question.

  1999cited by this paper
• Enantioselective induction of cyclophosphamide metabolism by phenytoin.

  1999cited by this paper
• Monospecific antipeptide antibody to cytochrome P-450 2B6.

  1999cited by this paper
• Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer.

  1999influential reference
• Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells

  1999cited by this paper
• Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer

  1999cited by this paper
• In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.

  1999cited by this paper
• Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism

  1999cited by this paper
• Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N -dechloroethylation of trofosfamide

  1999influential reference
• Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines.

  1999cited by this paper
• Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats.

  1999cited by this paper
• Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes.

  1999cited by this paper
• Isophosphoramide Mustard and Its Mechanism of Bisalkylation.

  1998influential reference
• Differential cytotoxicity of Ifosfamide and its metabolites in renal epithelial cell cultures.

  1998influential reference
• Use of mesna to prevent ifosfamide-induced urotoxicity

  1998cited by this paper
• Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo.

  1998cited by this paper
• Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy.

  1998influential reference
• The partitioning of phosphoramide mustard and its aziridinium ions among alkylation and P-N bond hydrolysis reactions.

  1998cited by this paper
• The influence of ifosfamide scheduling on acute nephrotoxicity in children.

  1997cited by this paper
• Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism.

  1997cited by this paper
• Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation

  1997cited by this paper
• Palliative chemotherapy in non-Hodgkin's lymphoma.

  1997cited by this paper
• Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes.

  1997influential reference

• Effects of Ertugliflozin and Lycopene on Ifosfamide-Induced Nephrotoxicity in Rats

  2025cites this paper
• The influence of genetic variation on late effects in childhood cancer survivors: An updated systematic review.

  2025cites this paper
• A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms

  2024cites this paper
• The roles of gold and platinum decoration and trapping on the B12N12 fullerene in improving the antitumor efficacy of ifosfamide: A DFT and spectroscopic study

  2024cites this paper
• Feasibility of nitride-based nanocages for the targeted delivery of ifosfamide: a DFT exploration

  2024cites this paper
• Recent advancements in the chemical sensing of anticancer alkylating agents

  2024cites this paper
• Chemotherapeutic drugs for soft tissue sarcomas: a review

  2023cites this paper
• Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies

  2023cites this paper
• Ifosfamide-induced nephrotoxicity in oncological patients

  2023influential citation
• Development of a new vesicular formulation for delivery of Ifosfamide: Evidence from in vitro, in vivo, and in silico experiments

  2023cites this paper
• A Portable Sensing Platform Using an Upconversion-Based Nanosensor for Visual Quantitative Monitoring of Mesna.

  2022cites this paper
• Gene-Directed Enzyme Prodrug Therapy by Dendrimer-Like Mesoporous Silica Nanoparticles against Tumor Cells

  2021cites this paper
• Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study

  2021cites this paper
• When I use a word . . . . Taking therapeutic care

  2021cites this paper
• Drug uptake-based chemoresistance in breast cancer treatment.

  2020cites this paper
• QUANTIFICATION OF 3-HYDROXYPROPYL MERCAPTURIC ACID IN THE URINE OF PATIENTS WITH BREAST CANCER TO MONITOR CYCLOPHOSPHAMIDE TOXICITY.

  2020cites this paper
• Causes and possibilities to circumvent cyclophosphamide toxicity

  2020cites this paper
• Cyclophosphamide in Drosophila promotes genes and transposable elements differential expression and mitochondrial dysfunction.

  2020cites this paper
• Effects of acrolein in comparison to its prodrug cyclophosphamide on human primary endothelial cells in vitro.

  2020cites this paper
• The Effectiveness of N-acetylcysteine in Alleviating Kidney Dysfunction in Ifosfamide-treated Rats

  2020influential citation
• Evaluation of mean platelet volume before and after cyclophosphamide treatment in systemic sclerosis associated interstitial lung disease

  2020cites this paper
• Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects

  2020cites this paper
• Analysis of CYP450 gene allelic variants can predict ifosfamide toxicity in Mexican paediatric patients

  2020cites this paper
• Prospective Pilot Study of Cyclophosphamide as an Adjunct Treatment in Patients With Adult-Onset Immunodeficiency Associated With Anti-interferon-γ Autoantibodies

  2020cites this paper
• Evaluation of the immunomodulatory properties and microbial bioburden of three commercial herbal mixtures sold in Awka, Anambra State Nigeria

  2019cites this paper
• Encapsulation efficiency of single-walled carbon nanotube for Ifosfamide anti-cancer drug

  2019cites this paper
• Panax ginseng is superior to vitamin E as a hepatoprotector against cyclophosphamide-induced liver damage.

  2019cites this paper
• Anti-cancer drugs in aquatic environment can cause cancer: Insight about mutagenicity in tadpoles.

  2019cites this paper
• Evidence for cytostatic effect of cyclophosphamide on human vein endothelial cells in cancer therapy: Preliminary in vitro results

  2018cites this paper
• From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles.

  2018cites this paper
• Study of the interactions between CD99, immunologic microenvironment and microRNAs and their prognostic significance in human osteosarcoma

  2018cites this paper
• Genotoxicity assessment of a selected cytostatic drug mixture in human lymphocytes: A study based on concentrations relevant for occupational exposure

  2018cites this paper
• Poly-isoprenylated ifosfamide analogs: Preactivated antitumor agents as free formulation or nanoassemblies.

  2017cites this paper
• Cyclophosphamide leads to persistent deficits in physical performance and in vivo mitochondria function in a mouse model of chemotherapy late effects

  2017cites this paper
• Inhibition of NF-κB/TNF-α pathway may be involved in the protective effect of resveratrol against cyclophosphamide-induced multi-organ toxicity

  2017cites this paper
• Stereochemical considerations in pharmacokinetic processes of representative antineoplastic agents

  2017cites this paper
• Acrolein and Human Disease: Untangling the Knotty Exposure Scenarios Accompanying Several Diverse Disorders.

  2017cites this paper
• Comparison of In Vitro Antileukemic Activity of 4-Hydroperoxyifosfamide and 4-Hydroperoxycyclophosphamide.

  2017cites this paper
• Cytotoxicity and genotoxicity of anticancer drug residues and their mixtures in experimental model with zebrafish liver cells.

  2017cites this paper
• Improving adenovirus-based immunotherapies for treatment of solid tumors

  2017cites this paper
• Synthesis and biochemical study on the effect of a novel gallium complex on tumor cell Invasion and matrix metalloproteinase activity in vitro.

  2017cites this paper
• Synthèse et évaluation pharmacologique d’analogues préactivés de l’ifosfamide : prodrogues et nanoparticules à visée antitumorale

  2017influential citation
• Enzyme/Prodrug Systems for Cancer Gene Therapy

  2016cites this paper
• Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma Treatment

  2016cites this paper
• Pharmacologic Basis for High‐dose Chemotherapy

  2016cites this paper
• Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide

  2016cites this paper
• The Protective Effect of Vanadium on Cyclophosphamide-Induced Teratogenesis in Mouse Fetus

  2016cites this paper
• Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma

  2016cites this paper
• Spectral heart rate variability in rats with cyclophosphamide-induced hemorrhagic cystitis treated with cyclooxygenase inhibitors.

  2015cites this paper
• Simultaneous quantification of preactivated ifosfamide derivatives and of 4-hydroxyifosfamide by high performance liquid chromatography-tandem mass spectrometry in mouse plasma and its application to a pharmacokinetic study.

  2015cites this paper
• Glutathione S-transferase P protects against cyclophosphamide-induced cardiotoxicity in mice.

  2015cites this paper
• A New Method to Quantify Ifosfamide Blood Levels Using Dried Blood Spots and UPLC-MS/MS in Paediatric Patients with Embryonic Solid Tumours

  2015cites this paper
• Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: synthesis and proof of concept.

  2015cites this paper
• Combined action of (-)-epigallocatechin-3-gallate and mafosfamide on HL-60 cells

  2014influential citation
• Pharmacokinetics of Anti-cancer Chemotherapy in Renal Insufficiency and Dialysis

  2014cites this paper
• From old alkylating agents to new minor groove binders.

  2014cites this paper
• The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies.

  2013cites this paper
• In vitro effects of new generation oxazaphosphorines on human promyelocytic leukemia cells.

  2013cites this paper
• Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation.

  2013cites this paper
• Duocarmycin Analogues into Potent Tumor Cytotoxins Specific Cytochrome P 450 2 W 1 Converts − Colon Cancer

  2013cites this paper
• Cancer Therapy : Preclinical Colon Cancer – Speci fi c Cytochrome P 450 2 W 1 Converts Duocarmycin Analogues into Potent Tumor Cytotoxins

  2013cites this paper
• Acrolein and chloroacetaldehyde: an examination of the cell and cell-free biomarkers of toxicity.

  2013cites this paper
• Surface-activated chemical ionization-electrospray mass spectrometry in the analysis of urinary thiodiglycolic acid.

  2013cites this paper
• In vitro cytotoxicity testing of new generation oxazaphosphorines against human histiocytic lymphoma cells.

  2013cites this paper
• [Classical oxazaphosphorines--metabolism and therapeutic properties--new implications].

  2013cites this paper
• Colon Cancer–Specific Cytochrome P450 2W1 Converts Duocarmycin Analogues into Potent Tumor Cytotoxins

  2013cites this paper
• Cytochrome P450 2W1 (CYP2W1) as a novel drug target in colon cancer therapy

  2013influential citation
• ON HUMAN ACUTE LYMPHOBLASTIC LEUKEMIA CELLS

  2012cites this paper
• Mechanisms of MAF Action on Cells

  2012cites this paper
• Comparative effects of new generation oxazaphosphorines on the size and viability of human acute myeloblastic leukemia cells.

  2012cites this paper
• Involvement of Four Different Intracellular Sites in Chloroacetaldehyde- Induced Oxidative Stress Cytotoxicity

  2012cites this paper
• Comparative effects of new generation oxazaphosphorines on the size and viability of human acute myeloblastic leukemia cells.

  2012cites this paper
• Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials.

  2012cites this paper
• Quantification of dimethyl-ifosfamide and its N-deschloropropylated metabolites in mouse plasma by liquid chromatography-tandem mass spectrometry.

  2011cites this paper
• The chemotherapy metabolite acrolein upregulates thrombin generation and impairs the protein C anticoagulant pathway in animal‐based and cell‐based models

  2011cites this paper
• Prodrugs—from Serendipity to Rational Design

  2011cites this paper
• In Vitro Breast Cancer Models as Useful Tools in Therapeutics

  2011cites this paper
• Modulation of Hemostatic Pathways by Breast Cancer Chemotherapy Agents

  2011cites this paper
• Glufosfamide as a new oxazaphosphorine anticancer agent

  2011cites this paper
• [Alkylating agents].

  2011cites this paper
• Protein modification by acrolein: relevance to pathological conditions and inhibition by aldehyde sequestering agents.

  2011cites this paper
• The Role of Constitutive Androstane Receptor in Oxazaphosphorine-Mediated Induction of Drug-Metabolizing Enzymes in Human Hepatocytes

  2011cites this paper
• Bioanalytical aspects of clinical mass balance studies in oncology.

  2011cites this paper